Testing a new drug for lung cancer that has spread to the brain or spinal fluid
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have non-small cell lung cancer that has come back or gotten worse after standard treatment.
- The cancer has spread to the fluid around your brain (cerebrospinal fluid) or the lining of your brain (leptomeninges), confirmed by a test or MRI.
- You are able to have a small device called an Ommaya reservoir placed in your head for drug delivery.
- Your cancer does not have a specific gene mutation that can be treated with a pill (some mutations are okay, but you must continue that pill if you're on it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
This trial tests a new drug, sacituzumab tirumotecan, given directly into the spinal fluid. It is for people with a specific type of lung cancer (EGFR-mutant) that has spread to the lining of the brain or spinal cord and has stopped responding to standard targeted pills.
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
Hear when a new Meningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.